Key Highlights

  • Net loss was USD 13.24 million, compared with USD 7.86 million.
  • Loss per share was USD 10.06, compared with USD 7.58.
  • Research and development expenses were USD 11.43 million, compared with USD 6.97 million.
  • Total Assets were USD 88.76 million at September 30, 2026.

TRex Bio (NASDAQ:TRXB) reported a net loss of USD 13.24 million for the third quarter of 2026, compared with USD 7.86 million in the prior-year quarter. Net loss per share attributable to common stockholders, basic and diluted, was USD 10.06, compared with USD 7.58.

For the nine months ended September 30, 2026, the net loss was USD 42.55 million, compared with USD 25.58 million, and net loss per share was USD 34.02, compared with USD 24.89.

Operating Expenses

Research and development expenses were USD 11.43 million, compared with USD 6.97 million, and general and administrative expenses were USD 2.49 million, compared with USD 1.74 million. Total operating expenses and loss from operations were USD 13.92 million, compared with USD 8.71 million.

Interest income was USD 768 thousand, compared with USD 853 thousand. Weighted average shares outstanding were 1,315,428, compared with 1,037,449. The per share figures reflect a Reverse Stock Split effected on October 2, 2026.

Nine-Month Results

For the nine months, Research and Development expenses were USD 37.46 million, compared with USD 21.94 million, and general and administrative expenses were USD 7.48 million, compared with USD 6.00 million. Total operating expenses were USD 44.93 million, compared with USD 27.94 million, and interest income was USD 2.52 million, compared with USD 2.42 million.

Balance Sheet and Offering

Cash and cash equivalents were USD 16.81 million at September 30, 2026, compared with USD 15.19 million at December 31, 2025, and marketable securities were USD 61.34 million, compared with USD 52.53 million. Total assets were USD 88.76 million, compared with USD 73.13 million, and total liabilities were USD 14.03 million, compared with USD 6.24 million.

The filing states that on October 2, 2026 the company effected a 1-for-3.8649 reverse stock split of its common stock. In October 2026, the company completed its initial public offering of 9,539,237 shares of common stock at USD 14.00 per share, including 1,205,903 shares sold pursuant to the underwriters' partial exercise of their option to purchase additional shares. The offering resulted in net proceeds of approximately USD 119.0 million.

The filing states that in June 2025 the company announced that it had initiated dosing in its first clinical trial for TRB-061, a novel TNFR2 agonist initially being developed for the treatment of atopic dermatitis.

The filing states that in January 2026 the company filed an Amended and Restated Certificate of Incorporation that increased the number of authorized shares of Series B redeemable convertible preferred stock from 27,510,762 shares to 43,388,910 shares.

As of September 30, 2026, the company had deferred offering costs of USD 4.6 million, included in other assets. Upon completion of the offering in October 2026, approximately USD 5.2 million of offering costs were reclassified as a reduction of the gross proceeds within additional paid-in capital.

TRex Bio Q3 2026 Earnings: Key Takeaways

TRex Bio reported a third quarter 2026 net loss of USD 13.24 million and a loss per share of USD 10.06. Total assets were USD 88.76 million at September 30, 2026.